Mycobacterium tuberculosis H37Rv (MIC, 2.5 g/ml), Mycobacterium bovis BCG (MIC, 0.5 g/ml), Mycobacterium avium (MIC, 2.0 g/ml), and Mycobacterium aurum A؉ (MIC, 2.0 g/ml), resulting in complete inhibition of mycobacteria grown on solid media. Importantly, a panel of clinical isolates of M. tuberculosis from different geographical areas with various drug resistance patterns were all sensitive to ISO in the range of 1 to 10 g/ml. Despite the availability of effective chemotherapies, tuberculosis, among those infectious diseases caused by a single etiology, is still a leading cause of death (22, 36) . The human immunodeficiency virus pandemic, which contributes substantially to the morbidity and mortality from tuberculosis (2, 6), and the emergence of multidrug-resistant strains of Mycobacterium tuberculosis (9, 37) have compounded the problem. Although infections with drug-sensitive strains of M. tuberculosis can be successfully cured with the currently used combination of iosoniazid (INH), rifampin, pyrazinamide, and ethambutol or streptomycin (8), the problem of drug resistance and the continuing rise in disease incidence have prompted research on new drug developments, particularly the search for new drug targets and the definition of mechanisms of drug resistance.
Despite the availability of effective chemotherapies, tuberculosis, among those infectious diseases caused by a single etiology, is still a leading cause of death (22, 36) . The human immunodeficiency virus pandemic, which contributes substantially to the morbidity and mortality from tuberculosis (2, 6) , and the emergence of multidrug-resistant strains of Mycobacterium tuberculosis (9, 37) have compounded the problem. Although infections with drug-sensitive strains of M. tuberculosis can be successfully cured with the currently used combination of iosoniazid (INH), rifampin, pyrazinamide, and ethambutol or streptomycin (8) , the problem of drug resistance and the continuing rise in disease incidence have prompted research on new drug developments, particularly the search for new drug targets and the definition of mechanisms of drug resistance.
INH, which is one of the most efficient and the most widely used antituberculosis drug (51) , has been the subject of intensive research on its modes of action and mechanisms of resistance. Both M. tuberculosis and Mycobacterium bovis BCG are extremely susceptible to INH, which is active in the range of 0.02 to 0.2 g/ml (3) . Early work demonstrated that INH specifically inhibits synthesis of mycolic acids in M. tuberculosis (39, 41, 45, 48) . INH is a prodrug which requires activation by the endogenous mycobacterial enzyme catalase-peroxidase (KatG) (20, 52) to form an electrophilic species (13, 46, 47) before reacting with targets such as InhA (1) . Other targets of the activated INH have been suggested to include two components of the type II fatty acid synthase system, a 12-kDa acyl carrier protein (ACP) designated AcpM and ␤-ketoacyl ACP synthase (KasA) (18, 19) . Ethionamide (ETH), a structural analog of INH, is a useful second-line antituberculosis drug (47) , and the two drugs have almost-identical effects in strongly inhibiting the synthesis of mycolic acids, slightly decreasing the synthesis of bound nonmycolic acids, and stimulating the synthesis of soluble lipids in susceptible species of mycobacteria (26, 49) . ETH is inhibitory for M. tuberculosis in liquid medium at about 1 g/ml and can be active against INH-resistant strains (47) . The work of Banerjee and colleagues demonstrated that a single mutation in the inhA gene, which is now known to encode an NADH-dependent 2-trans-enoyl ACP reductase, conferred resistance to both INH and ETH, leading to the impression that the modes of action of the drugs were identical (1) . However, there is not complete accord in the resistance patterns of ETH and INH; strains resistant to ETH can still be sensitive to INH, while, conversely, strains resistant to INH can show slightly increased sensitivity to ETH (30, 47) .
Isoxyl (ISO) (4,4Ј-diisoamyloxydiphenylthiourea; 4,4Ј-diisoamyloxythiocarbanilide; thiocarlide) (47) is an old drug used for the clinical treatment of tuberculosis in the 1960s. Urbancik (43, 44) and Titscher (42) demonstrated modest therapeutic efficacy of ISO monotherapy in cases of untreated pulmonary tuberculosis of various degrees of difficulty. The drug was able to convert about 25% of bacteriologically chronically positive cases to negative after 6 to 8 weeks of 6 g of ISO daily. However, when the treatment was extended to 10 to 18 weeks, about 50% of the patient population was converted to sputum negative (14) . Schmid (33) concluded that combined INH and ISO was more effective than monotherapy with either drug. It had been noted in the early 1950s that ISO exhibited strong antimycobacterial activity in vitro (47) . A note from Winder et al. in 1971 (49) showed that, like INH and ETH, ISO strongly inhibited mycolic acid synthesis in M. bovis during 6 h of exposure to 10 g/ml. ISO also partially inhibited the synthesis of the fatty acids of free lipids, which were stimulated by INH and ETH. This is the extent of published work conducted on the mechanisms of action of ISO. Consequently, we examined the efficacy of ISO in an attempt to decipher its mode of action.
MATERIALS AND METHODS
Growth and maintenance of mycobacterial strains. M. tuberculosis H37Ra (TMCC 25711), M. bovis BCG 1173P2, and Mycobacterium avium 724 were grown in 250-ml tissue culture flasks containing 50 ml of liquid Sauton medium and were incubated without agitation. Cells were grown to mid-exponential phase (for M. tuberculosis, ϳ21 days; for M. bovis BCG, ϳ14 days; and for M. avium, ϳ10 days) and harvested, and sterile glycerol was added to a final concentration of 10%. Cell suspensions were dispensed into tubes and stored at Ϫ70°C until required. Thawed suspensions were added to 50 ml of Sauton medium to yield identical cultures for further studies. The fast-growing Mycobacterium aurum Aϩ (from GlaxoWellcome, Stevenage, United Kingdom), which is sensitive to INH, was grown in nutrient broth (Difco Laboratories, Detroit, Mich.) containing 0.05% Tween 80. Cells were incubated to mid-log phase (ϳ5 days) at 37°C with shaking, as previously described (25) . Mycobacterium smegmatis mc 2 155 was grown in 250-ml Erlenmeyer flasks containing 100 ml of Sauton medium. Cells were incubated at 37°C with shaking for 4 days, and growth was monitored by measuring the A 600 . Virulent M. tuberculosis H37Rv (TMCC 102) and Erdman (TMCC 107) were grown in 250-ml Erlenmeyer flasks containing 100 ml of Sauton medium and incubated to mid-exponential phase at 37°C with shaking. A variety of human clinical isolates of M. tuberculosis had been stored in 2-ml aliquots and frozen at Ϫ70°C until used. The frozen stocks were counted by serial dilution in saline and plating onto 7H11 agar. The varied drug resistance patterns of these strains are shown in Table 1 . Drug resistance profiles were identified at the time of collection, as described elsewhere (24, 29) .
Determination of the MICs of ISO and its derivatives. ISO was a gift from M. J. Colston and P. Draper, National Institute of Medical Research, London, United Kingdom. Derivatives of ISO included para-alkoxy, para-alkyl, and other substituted thioureas (Table 2) ; the synthesis of ISO and its derivatives will be documented separately. The MICs of ISO and its derivatives on solid medium were determined by the microdrop agar proportion test, which was modified from the method of McClatchy (17) . Briefly, a series of 10-fold dilutions of cultures of M. tuberculosis H37Ra and H37Rv, M. tuberculosis Erdman, M. bovis BCG, and M. aurum Aϩ were prepared by using phosphate-buffered saline (8 g of NaCl, 0.2 g of KCl, 1.44 g of Na 2 HPO 4 , and 0.24 g of KH 2 PO 4 in 1,000 ml of distilled H 2 O, adjusted to pH 7.4) as a diluent. An aliquot (5 l) of each dilution was spotted on plates of 7H11 agar (Difco) containing oleic acid-albumin-dextrose-citric acid (OADC) as a supplement (7) and 0.1, 0.5, 1.0, 2.0, 2.5, 5.0, 10.0, and 20.0 g of each tested drug per ml. The plates were incubated at 37°C (ϳ4 days for M. smegmatis mc 2 155 and M. aurum Aϩ, ϳ12 days for M. avium, ϳ14 days for M. bovis BCG, and ϳ21 days for M. tuberculosis), and the number of viable bacteria was scored by counting colonies. The MIC was defined as the lowest concentration of ISO or its derivatives resulting in a 99% reduction in the number of colonies on that plate compared to those on a plate free of the drug at the same suspension of the culture dilution.
The analysis of growth curves and the estimation of broth MICs of ISO for both M. tuberculosis H37Ra and M. bovis BCG were performed in Sauton medium. Subcultures from master cell stocks were incubated to mid-exponential phase (A 600 , ϳ0.600), and 500 l of culture was inoculated in triplicate into 13-by 100-mm culture tubes containing 4.5 ml of fresh Sauton medium. The cultures were incubated at 37°C with gentle agitation until early exponential phase (A 600 , ϳ0.250), at which time ISO was added to cultures to final concentrations of 1.0 to 8.0 g/ml in 1% dimethyl sulfoxide (DMSO). The cultures were then subjected to gentle agitation with small magnetic stirrer bars and incubated at 37°C, and growth was monitored by measuring the A 600 with a Bausch & Lomb Spectronic 1001 spectrophotometer once a day. The broth MIC was defined as the lowest concentration able to stop cell growth definitely after one doubling time (26) . In all of the experiments, the stocks of ISO and its new derivatives were prepared in DMSO, and it was verified that at concentrations of up to 2% (vol/vol), the solvent had no effect on growth of these bacteria.
Drug susceptibility testing of drug-resistant clinical isolates of M. tuberculosis. A panel of clinical isolates of drug-resistant strains of M. tuberculosis from different geographical areas with various drug resistance patterns were diluted in microplates with phosphate-buffered saline to a final concentration of 10 6 CFU/ml for each strain. A sample (5 l) of the 10 6 -CFU/ml dilution was then spotted on 7H11 supplemented with OADC and containing ISO at different concentrations (1.0, 2.0, 5.0, and 10.0 g/ml and no ISO in a control plate). After inoculation of drug-resistant strains, the plates were incubated at 37°C for 21 days. Susceptibility of strains to ISO was defined as the absence of colonies on plates after exposure of organisms to ISO for 21 days.
Incorporation of [1,2-14 C]acetate into fatty acids and mycolic acids. M. bovis BCG and M. tuberculosis H37Rv were grown in 5 ml of Sauton medium in a set of culture tubes to early exponential phase, at which point ISO was added (other drugs tested included INH, ETH, and the butyl derivative of ISO). The cells were then incubated with gentle shaking for 10 h prior to addition of [1,2- 14 C]acetate (Na salt; 58 mCi/mmol; Dupont NEN, Boston, Mass.) at 1 Ci/ml to both control and drug-treated cultures, which were further incubated at 37°C with gentle agitation for an additional 24 h. The resulting 14 C-labeled cells were harvested by centrifugation at 2,500 ϫ g and washed twice with saline and once with sterile water (35) . In parallel experiments, M. aurum Aϩ was grown in nutrient broth to early exponential phase, preincubated with ISO for 6 h, and exposed to [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]acetate for 12 h.
Determination of the effects of ISO, INH, and ETH on mycolic acid biosynthesis. The 14 C-labeled control and drug-treated cells were resuspended in 2 ml of 15% tetrabutylammonium hydroxide (Sigma Chemical Co., St. Louis, Mo.) and saponified at 100°C overnight. After cooling, 2 ml of water, 3 ml of dichloromethane, and 300 l of iodomethane (Aldrich Chemical Co., Milwaukee, Wis.) were added to the entire reaction mixture, which was then shaken on a rolling shaker for 1 h. After centrifugation, the upper layer was discarded and the lower organic phase was washed three times with 3 ml of water. The washed lower phase was dried by nitrogen flow, extracted with 4 ml of diethyl ether, sonicated for 5 min, and centrifuged at 2,500 ϫ g (Beckman GPR desktop centrifuge). The ethereal extract was transferred into new 13-by 100-ml glass tubes, dried, and resuspended in 1.0 ml of dichloromethane for counting of radioactivity. Scintillation counting was conducted in vials containing 10 ml of EcoLume (ICN, Costa Mesa, Calif.) by using a Delta 300 scintillation system (Tracor Analytic, Elk Grove, Ill.). Equal volumes of this extract, which was composed of fatty acid methyl esters (FAMEs) and mycolic acid methyl esters (MAMEs), were applied to preparative thin-layer chromatography (TLC) plates of silica gel (5735 Silica Gel 60 F 254 ; Merck, Darmstadt, Germany) and developed six times in petroleum- Profiles were determined by a conventional proportion method (10, 11) . Strains were classified as multidrug resistant (MDR) if they were resistant to the major antituberculosis drugs INH and rifampin (Rif) or were resistant to these major drugs and one or more of the following: ethambutol (EMB), streptomycin (Str), kanamycin (Kan), cycloserine (Cyc) para-aminosalicylic acid (PAS), rifabutin (Rfb), ETH, amikacin (AMK), capreomycin (Cap), and pyrazinamide (PZA). The following responses were not determined: Rfb for CSU 22 ether-acetone (95:5) (35). The radioactive bands on the plate were also located and scanned for radioactivity by the BioScan System 200 Imaging Scanner with the Autochanger 3000. Each band was read stepwise for 10 min. Autoradiograms were produced by overnight exposure at Ϫ70°C to Kodak X-Omat AR film to reveal the 14 C-labeled FAME and MAME products. Separate bands of FAMEs and MAMEs were marked, cut from the TLC plates, and placed directly in 10 ml of EcoLume, and radioactivity was counted to estimate the degree of inhibition of the synthesis of FAMEs and individual population of MAMEs.
A more complete resolution of individual mycolate populations of M. bovis BCG, M. tuberculosis H37Rv, and M. aurum Aϩ was obtained by two-dimensional silver ion (Ag ϩ ) argentation TLC. To prepare TLC plates, 90% of a 10-by 10-cm silica gel plate was immersed in a 5% (wt/vol) aqueous silver nitrate solution, air dried, and activated at 100°C for 1 h prior to use. A known aliquot (ca. ϳ80,000 cpm) of the 14 C-labeled FAME-MAME mixture was then applied to the Ag ϩ TLC plate and developed in the first direction in hexane-ethyl acetate (95:5) two times. The plate was air dried and run in the second direction three times in petroleum ether-diethyl ether (85:15). The TLC plate was then exposed to Kodak X-Omat AR film at Ϫ70°C overnight, and individual FAMEs and MAMEs were marked.
In vitro murine macrophage model. Six-to 8-week-old female specific-pathogen-free C57BL/6 mice were purchased from Charles River Laboratories (Walmington, Mass.) and sacrificed by cervical dislocation, and femurs were Aϩ) in saline buffer were prepared, 5 l of each culture dilution was spotted on plates of 7H11 containing OADC, and the compounds were tested at 0.1, 0.5, 1.0, 2.0, 2.5, 5.0, 10.0, and 20.0 g/ml. The inoculated plates were incubated at 37°C as follows: M. tuberculosis for 21 days, M. bovis BCG for 14 days, M. avium for 12 days, and M. aurum Aϩ for 5 days. The number of colonies was then scored. The MIC was defined as the lowest concentration of compound that reduced 99% of the number of colonies on the plates compared to that on the control plate free of compound (38) . ND, not done. aseptically removed. The marrow was flushed out of the femurs with ice-cold Dulbecco's minimal essential medium (DMEM) supplemented with 10 mM HEPES, 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 U of penicillin per ml, 100 g of streptomycin per ml, 250 ng of amphotericin B per ml, and 10% L-929 fibroblast conditioned medium (supplemented DMEM [sDMEM]) and with 10% heated-inactivated, low-endotoxin fetal calf serum (Summit Biotechnologies, Inc., Fort Collins, Colo.). All other tissue culture reagents were purchased from Sigma Chemical Co. The marrow plugs were disrupted by gentle pipetting, washed twice, and plated at 10 6 cells per well in 24-well tissue culture microplates (Falcon 3047; Becton Dickinson, Lincoln Park, N.J.). After 48 h of incubation at 37°C in a 5% CO 2 and 96% humidity environment, the nonadherent cells were removed, and new sDMEM was added every 2 days. The sDMEM was changed every 2 days, and 2 days prior to infection, medium free of antibiotic (incomplete sDMEM) was added. Eight days after plating, macrophage cells were infected with 10 6 CFU of M. tuberculosis Erdman in 200 l of medium for 2 h. Macrophages were then extensively washed to remove extracellular bacteria and incubated in incomplete sDMEM containing ISO at the concentrations given in Fig. 6A . The series of concentrations of the butyl derivatives of ISO used are given in Fig. 6B . Macrophage cells were lysed in 1 ml of distilled water with 0.05% Tween 80 after 6 days of incubation. Three 10-fold dilutions were made, and 0.1 ml from each dilution was plated on 7H11 medium (Difco) and incubated in a 37°C dry-air incubator. The number of viable bacteria in each well was scored by counting the number of colonies resulting from each dilution on 7H11 plates. As a control, cells in several wells were lysed immediately after the initial infection to determine the number of bacteria phagocytosed and to assess the extent of growth over time.
Determination of possible in vitro toxicities of ISO and the butyl derivative by microplate alamar blue assay. Murine macrophages were prepared from C57BL/6 mice as described above. On day 6 after plating, the sDMEM was changed, and a fresh 2-ml aliquot of incomplete DMEM was added to each well. On day 8, the old medium was removed, and 1.8 ml of incomplete medium containing ISO or the butyl derivative of ISO at concentrations of 2.0, 1.0, 0.5, 0.25, 0.125, 0.0625, 0.032, and 0.017 g/ml was added with 200 l of alamar blue reagent (AccuMed International, Cleveland, Ohio), and plates were incubated at 37°C in the controlled-humidity and -CO 2 environment. The color of the alamar blue dye mixed with incomplete DMEM and the cell morphology were observed periodically within 3 days. 
RESULTS

Determination of MICs of ISO and ISO derivatives.
It is impossible to find accord in the literature on a standardized means of measuring MICs applicable to the different physical properties of drugs and different mycobacteria. Accordingly, MICs were evaluated under the defined conditions described in Materials and Methods, with species selected to reflect most of the known mycolic acid molecular types. ISO and a series of its derivatives with various substituted side chains were subjected to a preliminary evaluation of their in vitro activities against various species of mycobacteria by applying our defined quantitative agar plate proportion test involving use of 7H11 solid medium containing the OADC supplement. The MIC of ISO for M. tuberculosis was in the range of Ͻ1.0 to 2.5 g/ml, compared to published values of 0.02 to 0.2 g/ml for INH (3) and 5 to 10 g/ml for ETH (Table 3 ). The fast-growing mycobacterium M. aurum Aϩ was also susceptible to ISO, at a MIC of 2.0 g/ml. In contrast, M. smegmatis mc 2 155 was resistant to ISO as demonstrated by the presence of a number of colonies on 7H11 plates containing concentrations of ISO of as high as 200 g/ml (Table 3) . Thus, M. smegmatis mc 2 155 was excluded from further studies. The growth kinetics and the broth MIC of ISO for M. tuberculosis H37Ra were determined in Sauton medium. ISO at 3.0 g/ml substantially reduced the growth rates of M. tuberculosis and M. bovis BCG, and it inhibited growth entirely at a concentration of 4.0 g/ml, leading to the conclusion that the broth MIC of ISO for this strain of M. tuberculosis and M. bovis BCG is 4 g/ml (Fig. 1) . The MICs of most of the newly synthesized derivatives of ISO (Table 2) against M. tuberculosis were in the range of Ͻ0.1 to 2.5 g/ml ( Table 2 ). Most of the new derivatives were as effective or more so than ISO. We also examined the efficiency of ISO against a collection of drug-resistant clinical isolates of M. tuberculosis (Table 1) . Under the test conditions, ISO exhibited potent antimycobacterial activity against all evaluated strains. In particular, the strains resistant to the major first-line drugs (INH and rifampin) were susceptible to ISO in the range of 1 to 10 g/ml. No colonies of any of the drug-resistant strains were observed on plates containing 10 g of ISO per ml (Table 1) .
Selective effects of ISO and derivatives on inhibition of fatty acid and mycolic acid synthesis. M. bovis BCG was grown in the presence or absence of ISO at various concentrations, following which cultures were labeled with [1,2- 14 C]acetate. Combined MAMEs and FAMEs were extracted, resolved, and fractionated on TLC plates. The results demonstrated a decrease in the incorporation of radioactivity into FAMEs and MAMEs in the presence of ISO (Fig. 2) . Thus, the general effects of ISO were in accordance with those reported by Winder et al. (49) , i.e., a generalized inhibition of fatty acid and mycolic acid synthesis. The approach was extended to an examination of the effects of ISO on the individual classes of mycolates. Initial two-dimension TLC demonstrated that the mycolic acid composition of M. bovis BCG consisted primarily of ␣-mycolates and ketomycolates (Fig. 3) , and one-dimensional TLC revealed that, at the appropriate broth MIC of ISO for M. bovis BCG (4.0 g/ml), the syntheses of ␣-mycolates and ketomycolates were inhibited by 87.20 and 88.49%, respectively (Table 4) . A similar in vivo [1,2- 14 C]acetate labeling approach was extended to M. aurum Aϩ, which has the advantage of containing ␣-mycolates, ketomycolates, and waxester mycolates, and to M. tuberculosis H37Rv, which contains ␣-mycolates, methoxymycolates, and ketomycolates (Fig. 4) . ISO inhibited the syntheses of all of these classes of mycolic acids and also fatty acids of both M. tuberculosis H37Rv and M.
FIG. 1. Growth characteristics of M. tuberculosis H37Ra (A) and M. bovis BCG (B)
and effects of ISO on growth rates. Cells were grown in Sauton medium to an approximate A 600 of 0.250 at 600 nm in a set of culture tubes. ISO in DMSO was added at the indicated concentrations; an equivalent amount of 1% DMSO was added to control cultures. Cells were further incubated and monitored for growth rates once a day. In the presence of 3 g of ISO per ml, the growth rate of M. tuberculosis H37Ra was reduced, and at 4 g/ml, ISO completely inhibited growth. Thus, the broth MIC of ISO against M. tuberculosis H37Ra was estimated to be 4 g/ml. For M. bovis BCG in broth culture, the MIC of ISO was 4 g/ml. Each data point represents the mean of triplicate readings of A 600 . M. avium.............................................................................. a MICs were determined on solid medium under defined conditions as described in Materials and Methods; i.e., the MIC of ISO was defined as the lowest concentration of ISO that completely inhibited 99% of the growth of the organism (38) . Different mycobacterial species reflecting the various types of mycolic acids were included in the assay. The strains most susceptible to ISO then were chosen for further studies on its mode of action.
aurum Aϩ (Fig. 4 and 5) . According to the results of onedimensional TLC, ISO at its respective MICs inhibited the synthesis of ␣-mycolate by 87.10%, of ketomycolate by 87.20%, and of wax-ester mycolate by 86.48% in the case of M. aurum Aϩ and inhibited the synthesis of ␣-mycolate by 91.61%, of methoxymycolate by 94.29%, and of ketomycolate by 91.12% in the case of M. tuberculosis H37Rv (Fig. 5) .
Comparisons of the effects of ISO with those of INH and ETH.
Comparison of the effects of ISO and its derivatives to those of INH and ETH on mycolic acid biosynthesis was studied through cell labeling with [1,2- 14 C]acetate. The effects of all of these drugs were similar in that the synthesis of mycolic acids was inhibited. However, as reported previously (49), both INH and ETH slightly stimulated fatty acid synthesis upon treatment of mycobacteria with INH at concentrations of 0.01, 0.02, 0.1, and 1.0 g/ml and with ETH at 1.0, 2.0, 5.0, and 10 g/ml, whereas ISO and its derivatives inhibited these types of lipids (Table 4) .
Effect of ISO and the butyl derivative on viable M. tuberculosis in an in vitro bone marrow macrophage assay: absence of cytotoxicity. The addition of ISO to macrophage cultures containing M. tuberculosis Erdman resulted in bacterial killing in a dose-dependent manner (Fig. 6 ). In the absence of ISO, viable 14 C]acetate of 1 Ci/ml, and cultures were further incubated with gentle agitation at 37°C. Labeled FAMEs and MAMEs were extracted as described in Materials and Methods. The labeling times were 12 h for M. aurum Aϩ and 24 h for M. tuberculosis H37Ra and M. bovis BCG. About 80,000 cpm of each extract was applied to two-dimensional silver ion argentation TLC plates, which were developed twice in one direction in hexane-ethyl acetate (95:5) and three times in a second direction in petroleum ether-diethyl ether (85:15). Autoradiograms were obtained after exposure to Kodak X-Omat AR film at Ϫ70°C for 24 h. a Percent inhibition was determined based on the percent difference in incorporation of [1,2- 14 C]acetate into the free fatty acids and mycolic acids in the presence and absence of the drug. A negative value indicates stimulation of activity. All four drugs inhibited the synthesis of alpha-and ketomycolates. The difference in the effect on fatty acid synthesis is that INH and ETH stimulate the synthesis of short-chain fatty acids, whereas ISO and its derivative inhibit this activity.
bacteria grew to log 3.79 within 6 days, while in its presence, not only was growth inhibited but there was a reduction in the initial inoculum, indicating some bactericidal activity. The butyl derivative of ISO showed greater bactericidal activity in that it completely reduced the number of viable intracellular bacteria in macrophage cells at a concentration of 1.5 g/ml (Fig.  6) .
The alamar blue oxidation-reduction dye was applied as an indicator of the effects of ISO and the butyl derivative on macrophage cell viability. In this assay, the blue oxidized form becomes red due to the normal redox reactions within macrophage cells, and thus the red color represents cell viability. Mouse macrophage cells were grown in tissue microplates and treated with ISO or the butyl derivative. When the alamar blue dye was mixed with incomplete DMEM, the color was purple. All of the dilutions that contained ISO up to the highest tested concentration (2 g/ml) exhibited the red color. Likewise, cells treated with the butyl derivative of ISO maintained their viability. Accordingly, this thiourea is apparently not acutely toxic for mouse macrophages.
DISCUSSION
The slow-growing mycobacteria used in this study, i.e., M. tuberculosis, M. bovis BCG, and M. avium, doubled about every 18 to 26 h and thus yielded colonies from single cells in 14 to 21 days. In contrast, the fast-growing mycobacteria, M. aurum Aϩ and M. smegmatis mc 2 155, have doubling times of 2 to 3 h and yield colonies from a single cell in 3 to 4 days. The act of growing cells in tissue culture flasks without agitation in the case of M. tuberculosis, M. bovis BCG, and M. avium yielded high levels of reasonably unclumped viable cells. These species of Mycobacterium were included in preliminary experiments in order to identify ISO-susceptible and -resistant strains and to identify a set of suitable organisms for subsequent biochemical and genetic studies. The results of the MIC studies show that ISO is capable of inhibiting the growth of various mycobacteria within a narrow range of low concentrations. Importantly, a panel of virulent clinical isolates of M. tuberculosis also exhibited susceptibility to ISO when exposed to ISO in the range of 1.0 to 10.0 g/ml. Some virulent strains appeared to be less susceptible, while others showed evidence of high susceptibility to ISO even at the very low concentration of 1.0 g/ml. It is clear, however, that all of the clinical isolates of M. tuberculosis, which varied in patterns of resistance to other drugs (Table 1) , were consistently susceptible to ISO at a concentration of 10 g/ml. The suggestion is that ISO may be suitable for the treatment of tuberculosis, particularly the multidrug-resistant kind.
ISO (compound B27 in Table 2 ) is a substituted diacyl thiourea, and previous studies had demonstrated that the thiourea nucleus is required for antimycobacterial activity. In the hope of generating more-effective variants, random substitutions were made in the side chains attached to this key structure. This strategy resulted in an array of new ISO derivatives with variations in the symmetry and asymmetry of the side chains (Table 2) attached to the key structure. Some thioureas substituted in the para and paraЈ positions by alkyl, alkoxy, or sulfur functional groups were transformed from inactive thiocarbanilides into substances with considerable antimycobacterial activity. For instance, the butyl derivative of ISO (compound B01 in Table 2 ), the first synthesized ISO derivative, possessed low MICs (0.1 to 0.5 g/ml) and was chosen for further evaluation of its effects on mycobacteria. Replacement of the oxygen with sulfur in the side chain(s) provided extremely high antibacterial activity against M. tuberculosis, as demonstrated by low MICs of Ͻ0.1 for B25 and B33 and 1.0 for JDD38. Thus, several of the ISO derivatives with various side chains of allyl, alkoxy, and alkylthio units were superior to the parent compound in their activities against M. tuberculosis. Other slow growers, including M. bovis BCG and M. avium, were also susceptible to ISO and its derivatives within a narrow range of low MICs. The present results suggest that a concerted approach to chemical modification of the basic thiourea nucleus of ISO would lead to even more-powerful inhibitors of M. tuberculosis and M. avium.
The range of mycobacteria selected for the present study was based on their susceptibility to ISO and range of constituent mycolic acids (21) . The most-susceptible species, M. bovis BCG, M. tuberculosis H37Rv, and M. aurum Aϩ, which also presented a representative spectrum of mycolic acids, were chosen to analyze the effects of ISO on mycolic acid synthesis through whole-cell labeling with [1,2- 14 C]acetate. Previous reports had indicated that prolonged exposure of mycobacteria to a low concentration of drugs, rather than short exposure to higher concentrations, provides a better gauge of its effects on bacterial metabolism (30, 47) . Thus, the effects of ISO on mycolic acid synthesis could be clearly seen when the drug exposure times were 34 h for M. bovis BCG and M. tuberculosis H37Rv and 18 h for M. aurum Aϩ. This approach allowed us to confirm that the mode of action of ISO is through the specific inhibition of mycolic acid synthesis and that the inhibitory effect of ISO on mycolic acid synthesis is dose dependent (Fig. 4 and 5) . Based on the effects of ISO on the different species of mycobacteria, it can be concluded that ISO inhibited the synthesis of all types of mycolic acids, consistent with earlier observations (47) . The naturally high resistance of M. smegmatis to ISO is striking and cannot be explained at this time.
The use of an in vitro macrophage model allowed an assessment of the ability of ISO and its butyl derivative to cross membranes and target viable bacteria within the confines of the macrophage and phagosome. The drugs also demonstrated strong intracellular bactericidal activity by reducing the initial inoculum of virulent M. tuberculosis, suggesting cidal rather than static action.
INH and ETH are specific antituberculosis drugs which clearly affect mycolic acid synthesis (19, 26, 47) . INH, and apparently ETH, first requires conversion to an activated form, either an isonicotinic acyl anion (34) or an isonicotinic acyl radical (13) , by the mycobacterial catalase-peroxidase enzyme (KatG) (13, 19, 52) before it exerts its lethal effect on mycolic acid biosynthesis. The activated form of INH is capable of attaching to NAD(H) as it is bound to the active site of InhA to generate a covalent INH-NAD adduct (31) . InhA is a longchain (C 12 to C 24 ) enoyl ACP-dependent reductase (27, 32) which catalyze the NADH-dependent reduction of a double bond at position 2 of a growing fatty acid chain linked to ACP. However, it had previously been observed (39) (40) (41) and was recently reconfirmed (19) that M. tuberculosis, in response to INH treatment, caused an accumulation of saturated hexacosanoic acid (C 26:0 ). It is now known that this acyl group is attached to a 12-kDa ACP (AcpM) (19) , and, according to this Labeling of cultures was performed in triplicate and terminated by treatment with 15% tetrabutylammonium hydroxide at 100°C overnight. The FAME and MAME bands arising from each organism were isolated, and radioactivity was counted.
FIG. 6. Bactericidal activity of ISO and its butyl derivative against M. tuberculosis Erdman in infected macrophage cell cultures. Murine bone marrowderived macrophages were infected with 10 6 bacteria for 2 h, extracellular bacteria were removed, and infected macrophages were incubated with various concentrations of ISO or the butyl derivative for 6 days. Macrophage lysates were then individually plated on 7H11 agar to score the number of viable bacteria. (A) Bactericidal activity of ISO inside murine macrophage cells. ISO at a concentration of 2.5 g/ml resulted in a 4-log-unit reduction in viable bacteria. (B) Bactericidal activity of the butyl derivative of ISO. At a concentration of 1.5 g/ml, the butyl derivative completely killed intracellular mycobacteria, resulting in a 3.72-log-unit reduction in viable bacteria. latest work, the ␤-ketoacyl ACP synthase in association with AcpM is the target of INH (19) . Thus, at this point, the exact sites and mechanisms of action of INH for mycolic acid synthesis are varied and may be species dependent.
Unlike INH and ETH, ISO is not a nicotinamide derivative but has a higher molecular weight and is a thiourea modified by long hydrophobic side chains. It is difficult to envisage ISO as a prodrug capable of being converted into an electrophile. Hence, it is unlikely to form a complex with NAD ϩ at the InhA or any other active site. Moreover, the utilization of [1-2, 14 C] acetate as a precursor of fatty acid and mycolic acid synthesis demonstrated that ISO is distinct from INH and ETH in that it inhibits the synthesis of short-chain fatty acids (Table 4) , a result that is consistent with the previous report on the mode of action of ISO (47) and suggests that the targets of ISO may lie at the points shared in the synthesis by both short-chain fatty acids and mycolic acids. The mycobacterial multifunctional FAS-I, the monofunctional FAS-II, and the largely undefined mycolic acid synthetase are responsible for fatty acid and mycolic acid synthesis. FAS-I is a single polypeptide with multiple catalytic activities that generate several shorter coenzyme A (CoA) esters from the acetyl-CoA primer (12, 15, 16, 23) , and the primary products of the de novo FAS-I system are C 16 to C 18 and C 24 to C 26 fatty acyl-CoA derivatives (4, 5) . Therefore, FAS-I creates the precursor for further elongation. FAS-II consists of dissociable enzyme components which act on a substrate bound to ACP. FAS-II is incapable of de novo fatty acid synthesis but instead elongates a C 16 fatty acid primer (palmitoyl-ACP) to fatty acids ranging from C 24 to C 56 in length (28) . Several different components of FAS-II were reported to be targets of INH, including the enoyl-ACP reductase (InhA) (1) and the ketoacyl-ACP synthase (KasA) in association with the ACP AcpM (19) . It seems likely that ISO acts on other components of FAS-II, resulting in the inhibition of short-chain fatty acid synthesis, an effect distinct from that of INH. The mode of action of ISO remains elusive. An understanding of the specific mode of action of ISO is important in the search for new antimycobacterial drug targets and for the development of more effective chemotherapy. Furthermore, effects on fatty acid synthesis which differed from those of INH and ETH provide the prospects of identifying new fatty acid biosynthesis genes in addition to mycolic acid biosynthesis genes.
